(Total Views: 505)
Posted On: 09/09/2024 8:33:59 AM
Post# of 154684
Good morning to all longs.
On the same subject. Sharing a good read on the CCL5/CCR5 Axis in Cancer Progression. I think it has not been shared before, but if so, apologies in advance.
https://www.mdpi.com/2072-6694/12/7/1765
Our time will come ....
On the same subject. Sharing a good read on the CCL5/CCR5 Axis in Cancer Progression. I think it has not been shared before, but if so, apologies in advance.
https://www.mdpi.com/2072-6694/12/7/1765
Quote:
Conclusions
Many preclinical studies in different cancer models have demonstrated the protumorigenic role of the CCL5/CCR5 axis, which is involved not only in tumor growth and metastasis but also in the formation of an immunosuppressive and protective TME. Accordingly, the overexpression of CCL5 or CCR5 by cancer cells or tumor tissues has been found to correlate with poor prognosis and CCR5 expression by cancer cells to associate with a decreased activity of DNA damaging agents.
This evidence provides the basis for the clinical assessment in cancer treatment of the repurposed drug maraviroc, as a single agent or in combination with immune checkpoint inhibitors or DNA damaging agents to potentiate their cytotoxic activity, and of drugs capable to decrease CCL5 levels in tumor tissues.
Our time will come ....
(11)
(0)
